论文部分内容阅读
目的:探讨消化性溃疡患者采用三联疗法治疗的临床效果。方法:将116例消化性溃疡患者随机分为对照组与观察组各58例,观察组患者采用呋喃唑酮、奥美拉唑与左氧氟沙星三联疗法,对照组患者给予呋喃唑酮、奥美拉唑与阿莫西林三联疗法,分别比较其临床疗效、不良反应及螺门幽杆菌清除率。结果:观察组患者的临床有效率为96.6%,幽门螺杆菌根除率为83.0%,均明显高于对照组,具有统计学意义(P<0.05);但两组患者的不良反应发生率比较无统计学意义(P>0.05)。结论:呋喃唑酮、奥美拉唑与左氧氟沙星三联疗法治疗消化性溃疡不仅能够迅速改善患者症状,促进溃疡范围减小,根除幽门螺杆菌,也具有良好的临床安全性。
Objective: To investigate the clinical effect of triple therapy in patients with peptic ulcer. Methods: One hundred and sixty-six patients with peptic ulcer were randomly divided into control group and observation group, with 58 cases in each group. Furazolidone, omeprazole and levofloxacin triple therapy were used in observation group. Furazolidone, omeprazole and amoxicillin Triple therapy, respectively, to compare their clinical efficacy, adverse reactions and Helicobacter pylori clearance rate. Results: The clinical effective rate in the observation group was 96.6%, and the eradication rate of Helicobacter pylori was 83.0%, which were significantly higher than those in the control group (P <0.05). However, the incidence of adverse reactions in both groups was no significant difference Statistical significance (P> 0.05). Conclusion: Furazolidone, omeprazole and levofloxacin triple therapy for peptic ulcer not only can rapidly improve the symptoms of patients, promote the reduction of ulcer area, eradicate Helicobacter pylori, also has good clinical safety.